Cyclerion Therapeutics (NASDAQ:KRSA) Upgraded to “Hold” at Zacks Research

by · The Markets Daily

Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) was upgraded by research analysts at Zacks Research to a “hold” rating in a report released on Wednesday, Zacks reports.

Cyclerion Therapeutics Trading Down 100.0%

About Cyclerion Therapeutics

(Get Free Report)

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.

Read More